Obtain Favorable Decision In Patent Infringement Litigation Related To Lenvatinib In The U.S.
29/05/2025 24:35
Eisai Co Ltd 4523.T: EISAI CO LTD - OBTAIN FAVORABLE DECISION IN PATENT INFRINGEMENT LITIGATION RELATED TO LENVATINIB IN THE U.S. EISAI CO LTD - SHILPA NOW IS NOT ABLE TO RECEIVE APPROVAL FROM FDA TO SELL ITS GENERIC VERSION OF LENVATINIB MESYLATE UNTIL AFTER THE PATENT AND RELATED EXCLUSIVITY EXPIRES IN FEBRUARY 2036 Source text: ID:nTSqb8b666 Further company coverage: 4523.T
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China